Boehringer Ingelheim: European Commission Approves JASCAYD, Bringing Well-tolerated, Novel Oral Treatment for Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis to the EU
July 18, 2026
July 18, 2026
INGELHEIM AM RHEIN, Germany, July 18 (TNSjou) -- Boehringer Ingelheim, a pharmaceutical company, issued the following news release on July 17, 2026:
* * *
European Commission approves JASCAYD(R), bringing well-tolerated, novel oral treatment for IPF and PPF to the EU
* JASCAYD(R) (nerandomilast) is the first oral, preferential PDE4B inhibitor approved in the European Union, delivering a novel mechanism of action with antifibrotic and immunomodulatory effect . . .
* * *
European Commission approves JASCAYD(R), bringing well-tolerated, novel oral treatment for IPF and PPF to the EU
* JASCAYD(R) (nerandomilast) is the first oral, preferential PDE4B inhibitor approved in the European Union, delivering a novel mechanism of action with antifibrotic and immunomodulatory effect . . .